Short answer
GeneDx Holdings Corp. (WGS) filed an 8-K current report with the SEC on November 18, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CEO Katherine Stueland exits by December 15, 2026, remains Executive Advisor through January 31, 2027.
GeneDx Holdings Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO Katherine Stueland exits by December 15, 2026, remains Executive Advisor through January 31, 2027
- Everett Cunningham becomes CEO and Class II director, with a term through GeneDx’s 2029 annual meeting
- New CEO compensation: $750,000 base salary, 100% target bonus, and $1,050,000 sign-on bonus
- Equity package totals $20 million initially: $10 million time-based RSUs and $10 million performance-based RSUs
- Transition increases execution focus, with Cunningham bringing senior commercial experience from Quanterix, Illumina, Exact Sciences, and Quest Diagnostics
Item 7.01 · Regulation FD Disclosure
- Press release announces Mr. Cunningham’s appointment
- Ms. Stueland’s service ended, signaling a leadership transition
- Exhibit 99.1 contains the substantive appointment and departure details
Item EX-99.1 · Exhibit EX-99.1
- Everett Cunningham appointed CEO and director by December 15, 2026, signaling a commercial-growth focus
- Katherine Stueland departing CEO and director after five-and-a-half years, remaining as adviser through January 31, 2027
- Cunningham brings 35-plus years across Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics and Pfizer
- Mark Gardner remains President, reporting to Cunningham, limiting broader leadership disruption
- GeneDx reaffirmed full-year 2026 financial guidance, reducing immediate earnings uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GeneDx Holdings Corp. 8-K filings
Get the next WGS 8-K as it lands
Follow WGS for push alerts, or ask the research agent what this filing means.